Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745578 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.1101678 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSMA-targeted radioligand therapy in metastatic prostate cancer: Comprehensive analysis of recent evidence.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Gruppo Ospedaliero Moncucco SA, Clinica Moncucco, Via Soldino 10, Lugano, 6900, Switzerland.
Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate?
Eur Urol
December 2024
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey. Electronic address:
Time to Refine Prostate Cancer Epidemiology: Defining New Endpoints for Effective Screening and Causal Epidemiological Studies.
Eur Urol Oncol
December 2024
Department of Urology, Medical University of Vienna, Vienna, Austria.
Current epidemiological indicators reflect the prevalence of prostate-specific antigen (PSA) testing rather than the actual incidence of clinically significant prostate cancer. These indicators are also biased because of the variability of the PSA test. We therefore need to adopt new reliable criteria in causal epidemiological studies and screening programs.
View Article and Find Full Text PDFEditorial: Androgen-dependent diseases and their treatment.
Front Endocrinol (Lausanne)
December 2024
Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.
Refining the need for prostate biopsy and the evolving role of MRI.
Eur Radiol
December 2024
Oncologic Imaging Division, Department of Radiology, NYU Langone Health, New York, NY, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!